Vivoryon Therapeutics (VVY) H2 2024 earnings summary

Executive summary

• Achieved a strategic shift to focus on kidney disease, with varoglutamstat showing robust clinical and preclinical evidence for improving kidney function, especially in diabetic populations, supported by two independent Phase 2 studies and meta-analysis confirming efficacy and safety.

• Discontinued Alzheimer's disease program after lack of efficacy, redirecting resources to kidney disease and expanding the executive team with a new COO.

• Strengthened IP position with new U.S. composition of matter patent for varoglutamstat, extending exclusivity potentially to 2049, and filed additional patents for combination therapy.

• Extended cash runway into January 2026 through prudent resource management and a Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors for up to EUR 15 million.

Financial highlights

• No revenue recognized in 2024; prior revenue was related to a 2021 licensing milestone.

• Research and development expenses decreased to EUR 14.1 million in 2024 from EUR 17.6 million in 2023, mainly due to lower third-party and clinical costs.

• General and administrative expenses fell to EUR 6.9 million from EUR 8.6 million, driven by reduced personnel and board costs.

• Net loss for 2024 was EUR 20.6 million, improved from EUR 28.3 million in 2023.

• Cash and cash equivalents at year-end 2024 were EUR 9.4 million, with financial assets totaling EUR 18.56 million.

Outlook and guidance

• Cash runway expected to fund operations through January 2026, not including potential SEPA proceeds.

• Initiation of Phase 2b DKD study is a key priority, contingent on securing additional funding or partnerships.

• Ongoing efforts to strengthen IP and advance next-generation QPCT/L inhibitors.